|Bid||109.34 x 1100|
|Ask||109.88 x 1400|
|Day's Range||109.40 - 110.47|
|52 Week Range||58.59 - 110.47|
|Beta (3Y Monthly)||1.41|
|PE Ratio (TTM)||13.53|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Pharmaceutical company Bristol-Myers has been in a downtrend since 2016 and after unveiling its planned merger with Celgene. Is now the right time to buy BMY stock?
The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.
Celgene (CELG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Celgene (CELG) and partner Acceleron obtain FDA approval for Reblozyl for the treatment of anemia in adult patients with beta thalassemia.
Shares of Acceleron Pharma popped Friday after the biotech company gained Food and Drug Administration approval for a Celgene-partnered anemia treatment in patients with beta thalassemia.
Shares of Celgene Corp. [s:celg] rose 0.34% in afternoon trading after the U.S. Food and Drug Administration approved Reblozyl. The drug, which treats anemia in patients with beta thalassemia, a rare blood disorder, was developed jointly by the drugmaker and Acceleron Pharma Inc. . It's the first FDA-approved therapy for Acceleron. Acceleron shares were up about 6% to $43.17. Bristol-Myers Squibb 's acquisition of Celgene for $74 billion in cash and stock is expected to close by the end of the year. Celgene's stock is up roughly 70% year to date, while the S&P Index has gained 23% this year.
Luspatercept is one of the first treatments for beta thalassemia, a blood disorder being targeted by multiple local companies.
Celgene Corp's treatment for anemia in patients with beta thalassemia, a rare blood disorder, would be priced at $3,441 for a 25-milligram vial of the drug, partner Acceleron Pharma Inc said. The drug was jointly developed by Acceleron and Celgene, which is being bought by Bristol-Myers Squibb Co. A 75 mg vial of Reblozyl will be available at a wholesale acquisition cost of $10,323.53 per vial, Acceleron said.
Moody's Investors Service ("Moody's") confirmed the ratings of Bristol-Myers Squibb Company ("Bristol") including the A2 senior unsecured long-term rating and the Prime-1 commercial paper rating. "The confirmation of Bristol's A2 ratings reflects its solid business profile and strong financial profile following the pending acquisition of Celgene Corporation," stated Michael Levesque, Moody's Senior Vice President.
Celgene (CELG) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Shares of Amgen are on an upswing after the company won a patent battle over its drug Enbrel against Novartis subsidiary Sandoz. Is it time to buy shares of the massive biotech company?
The Zacks Analyst Blog Highlights: Facebook, JPMorgan Chase, Royal Dutch Shell, Starbucks and Celgene